Jun. 24 at 7:17 PM
H.C. Wainwright on
$CLYM (Buy;
$20): Budoprutug clinical data in idiopathic thrombocytopenic purpura underscores therapeutic potential.
$NVS $SNY AMGN UCBJY TAK
H.C. Wainwright added—Climb Bio recently reported initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients. The initial data were presented at the European Hematology Association (EHA) Congress 2026, which was held on June 11-14, 2026, in Stockholm, Sweden. Results to date support continued clinical evaluation of budoprutug in ITP; we reiterate our Buy rating and 12-month price target of
$20.
